Evidence map›Paper›PMID 38459443›Full record

ArticleBMC cancer2024

PErspective and current status of Radiotherapy Service in IRan (PERSIR)-1 study: assessment of current external beam radiotherapy facilities, staff and techniques compared to the international guidelines.

Arefeh Saeedian, Fatemeh-Sadat Tabatabaei, Amirali Azimi, Mohammad Babaei, Marzieh Lashkari, Ebrahim Esmati, Zeinab Abiar, Leila Moadabshoar, Saleh Sandoughdaran, Mitchell Kamrava and 2 more

Abstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Arefeh Saeedian *Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-1999-5776
Fatemeh-Sadat Tabatabaei *Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-2975-3543
Amirali Azimi *Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-7801-7855
Mohammad BabaeiDepartment of Radiation Oncology, Cancer Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran.
Marzieh LashkariRadiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-9286-0371
Ebrahim EsmatiRadiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Zeinab AbiarRadiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Leila MoadabshoarRadiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Saleh SandoughdaranSt Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK.
Mitchell KamravaRadiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Arya AminiDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, 91010, USA.
Reza GhalehtakiRadiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran. rghalehtaki@tums.ac.ir.ORCID http://orcid.org/0000-0003-1162-2019

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeRadiotherapy (RT) is an essential treatment modality against cancer and becoming even more in demand due to the anticipated increase in cancer incidence. Due to the rapid development of RT technologies amid financial challenges, we aimed to assess the available RT facilities and the issues with achieving health equity based on current equipment compared to the previous reports from Iran. MATERIALS AND

methodsA survey arranged by the Iran Cancer Institute's Radiation Oncology Research Center (RORC) was sent to all of the country's radiotherapy centers in 2022. Four components were retrieved: the reimbursement type, equipment, human resources, and patient load. To calculate the radiotherapy utilization rate (RUR), the Lancet Commission was used. The findings were compared with the previous national data.

resultsSeventy-six active radiotherapy centers with 123 Linear accelerators (LINACs) were identified. The centers have been directed in three ways. 10 (20 LINACs), 36 (50 LINACs), and 30 centers (53 LINACs) were charity-, private-, and public-based, respectively. Four provinces had no centers. There was no active intraoperative radiotherapy machine despite its availability in 4 centers. One orthovoltage X-ray machine was active and 14 brachytherapy devices were treating patients. There were 344, 252, and 419 active radiation oncologists, medical physicists, and radiation therapy technologists, respectively. The ratio of LINAC and radiation oncologists to one million populations was 1.68 and 4.10, respectively. Since 2017, 35±5 radiation oncology residents have been trained each year.

conclusionThere has been a notable growth in RT facilities since the previous reports and Iran's situation is currently acceptable among LMICs. However, there is an urgent need to improve the distribution of the RT infrastructure and provide more facilities that can deliver advanced techniques.

Indexed as

NeoplasmsRadiation OncologyHumansIranParticle AcceleratorsRadiotherapySurveys and QuestionnairesCancer care facilitiesDeveloping countriesGlobal healthIranRadiation oncologyServices accessibility

Identifiers

PMID38459443
PMCPMC10921664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.